Tehran University of Medical Sciences Archives of Anesthesiology and Critical Care 2423-5849 7 4 2021 10 01 253 277 Afsaneh Sadremomtaz XB20 Drug Design, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, Netherlands Javad Hashemi Department of Pathobiology and Laboratory Sciences, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran. Adeleh Sahebnasagh Clinical Research Center, Department of Internal Medicine, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran. Seyed Mohammad Nabavi Baqiyatallah Hospital, Baqiyatallah University of Medical Sciences, Tehran, Iran. Zayana M.Al-Dahmani Biochemistry Department, College of Medicine, Sultan Qaboos University, Alkhoud, Oman. Shayesteh Gheibi Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran Bita Shahrami Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran Reza Mosaed Department of Anesthesiology and Intensive Care, School of Medicine, Aja University of Medical Sciences, Tehran, Iran. Peyman Arfa Burn Intensive Care Unit, Shahid Motahari Burn Hospital, Iran University of Medical Sciences, Tehran, Iran Soheil Roshanzamiri Burn Intensive Care Unit, Shahid Motahari Burn Hospital, Iran University of Medical Sciences, Tehran, Iran Mojtaba Mojtahedzadeh Department of Clinical Pharmacy, Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran 2021 07 13 2021 07 31 At the end of 2019, Sars-CoV-2 was identified and has since spread in the world. Coronavirus is commonly caused by the upper respiratory tract and severe acute respiratory syndrome in humans. Due to the novel nature of the virus and high mortality among high-risk people, today health care providers used several medications with different mechanisms to overcome this virus. The course of COVID-19 represents three stages that have different symptoms and used different drugs depends on each stage.  Ultimately the minority of patients progress to stage III with high mortality. The aim of this study is a comprehensive review of COVID-19 adjuvant therapies. We explained the current study on the use of Glucocorticoids, Interferon, Vitamin C, Tocilizumab, Anakinra, Pentoxifylline, IVIG, Allopurinol, Ivermectin, and Selenium in sepsis, pneumonia, and ARDS and we suggested a new protocol for prescribing each medication currently used in COVID-19 Outbreak. At the end of 2019, Sars-CoV-2 was identified and has since spread in the world. Coronavirus is commonly caused by the upper respiratory tract and severe acute respiratory syndrome in humans. Due to the novel nature of the virus and high mortality among high-risk people, today health care providers used several medications with different mechanisms to overcome this virus. The course of COVID-19 represents three stages that have different symptoms and used different drugs depends on each stage.  Ultimately the minority of patients progress to stage III with high mortality. The aim of this study is a comprehensive review of COVID-19 adjuvant therapies. We explained the current study on the use of Glucocorticoids, Interferon, Vitamin C, Tocilizumab, Anakinra, Pentoxifylline, IVIG, Allopurinol, Ivermectin, and Selenium in sepsis, pneumonia, and ARDS and we suggested a new protocol for prescribing each medication currently used in COVID-19 Outbreak. https://aacc.tums.ac.ir/index.php/aacc/article/view/382